Results 81 to 90 of about 15,550 (253)

Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions [PDF]

, 2015
Small vessel disease encompasses lacunar stroke, white matter hyperintensities, lacunes and microbleeds. It causes a quarter of all ischemic strokes, is the commonest cause of vascular dementia, and the cause is incompletely understood.
Bath PMW, Ferlito S, Joanna M. Wardlaw, Philip M. Bath, Topol E   +4 more
core   +2 more sources

Critical evaluation of real‐world evidence of repurposable medicines in the Alzheimer's disease drug development pipeline using a target trial emulation

Alzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 12, Issue 1, January/March 2026.
Abstract INTRODUCTION Repurposing Food and Drug Administration (FDA)‐approved drugs could accelerate treatment development for Alzheimer's disease (AD). METHODS Using the MarketScan claims database (2011 to 2020), we applied a trial emulation approach in two base cohorts: (1) individuals with mild cognitive impairment (MCI cohort) and (2) individuals ...
Reina Tonegawa‐Kuji, Ehud Karavani, Michael Danziger, Pengyue Zhang, Yuan Hou, Yadi Zhou, Marina Bykova, Andrew A. Pieper, Michal Rosen‐Zvi, Jeffrey Cummings, Feixiong Cheng   +10 more
wiley   +1 more source

Cilostazol [PDF]

Reactions Weekly, 2020
  +4 more sources

Anticoagulant or Antithrombotic Therapy After Early Neurological Deterioration in Patients With Branch Atheromatous Disease Receiving Dual Antiplatelet Therapy

International Journal of Clinical Practice, Volume 2026, Issue 1, 2026.
Objective We evaluated the effectiveness and safety of adding tirofiban or argatroban after early neurological deterioration (END) in patients with branch atheromatous disease (BAD) receiving dual antiplatelet therapy and compared the outcomes with those of patients who continued dual antiplatelet therapy alone. Methods This retrospective study focused
Xuemin Zhong, Juan Yang, Ronghua Xu, Jian Wang, Nikhat Kaura   +4 more
wiley   +1 more source

Transcriptomic analysis reveals Cilostazol's role in ameliorating cardiovascular disease: Inhibition of monocyte-to-macrophage differentiation and reduction of endothelial cell reactive oxygen species production

Heliyon
Background: Cardiovascular diseases (CVDs) are the leading global cause of death, with atherosclerosis as the primary cause. Chronic inflammation, endothelial dysfunction, and the role of molecules like nitric oxide and reactive oxygen species are ...
Chia-Ning Fan, Tsung-Neng Tsai, Xin-Jie Lu, Hsing-Fan Lai, Chun-Hua Wang, Yi-Lin Chiu   +5 more
doaj   +1 more source

Phosphodiesterase 3 inhibition and cough in elderly asthmatics [PDF]

, 2005
Aims Cough is a common symptom of bronchial asthma, a chronic inflammatory airway disease. Recently, the therapeutic effects of selective phosphodiesterase (PDE) inhibitors have been focused on bronchial asthma. This study was designed to investigate the
20313645, 20313645, 21219, 21237, 21238, 21239, 21240, 297, 30231476, 30231476, 30231476, 44, 90190066, 90190066, Abo, Miki, Fujimura, Masaki, Ishiura, Yoshihisa, Myou, Shigeharu, Nakamura, Hiroyuki, Nobata, Kouichi, Oribe, Takayoshi   +20 more
core   +2 more sources

Effects of cilostazol on fracture healing: an experimental study

Acta Orthopaedica et Traumatologica Turcica, 2020
Objective: The aim of this experimental study was to examine the clinical, radiological and histological effects of cilostazol on fracture healing. Methods: A total of 60 Wistar albino male rats were divided into 2 groups: the study group (cilostazol ...
Alper Çıraklı, Taner Alıç, Yılmaz Şahin, Yılmaz Tomak   +3 more
doaj   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: Enzymes

British Journal of Pharmacology, Volume 182, Issue S1, Page S307-S403, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Doriano Fabbro, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Chloe J. Peach, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Stephanie Annett, Detlev Boison, Kathryn Elisa Burns, Carmen Dessauer, Jürg Gertsch, Nuala Ann Helsby, Angelo A. Izzo, Rennolds Ostrom, Ester Pagano, Andreas Papapetropoulos, Nigel J. Pyne, Susan Pyne, Tracy Robson, Roland Seifert, Johannes‐Peter Stasch, Csaba Szabo, Mario van der Stelt, Albert van der Vliet, Val Watts, Szu Shen Wong   +31 more
wiley   +1 more source

Cilostazol protects against degenerative cervical myelopathy injury and cell pyroptosis via TXNIP-NLRP3 pathway

Cell Division
Degenerative cervical myelopathy (DCM) is one of the most common and serious neurological diseases. Cilostazol has protective effects of anterior horn motor neurons and prevented the cell apoptosis. However, there was no literatures of Cilostazol on DCM.
Fei Xu, Zhuo Tian, Zhengguang Wang
doaj   +1 more source

Cilostazol protective effect on nedaplatin-induced genotoxicity in cultured human lymphocytes

Toxicology Reports
Background: Nedaplatin has demonstrated remarkable efficacy in combating various malignancies. However, the administration of nedaplatin has been associated with the induction of DNA damage within normal cells.
Karem H. Alzoubi, Abeer M. Rababa’h, Omar F. Khabour, Fian Nuseir   +3 more
doaj   +1 more source